TL;DR
- Monthly GLP-1 injections are in development.
- Pfizer and Amgen aim to reduce injection frequency.
- Patients report convenience with fewer injections.
- Side effects are similar to existing drugs.
- Monthly options could improve adherence.
For millions of people on weight loss drugs, the next big thing isn’t just shedding pounds; it’s shedding the hassle of frequent injections. Welcome to the future of weight management, where Pfizer and Amgen are shaking things up with monthly GLP-1 shots. That’s right, folks – fewer needles, more fabulousness!
Currently, many are stuck with weekly injections like Wegovy and Zepbound, which can feel like a full-time job. “Whether it’s a daily pill, a weekly injection or even a monthly injection, the more frequently a medication must be taken, the more opportunities there are to miss doses or stop treatment altogether,” says Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina. Who hasn’t had a moment of forgetfulness when life gets busy?
Dr. John Buse, an endocrinologist at the University of North Carolina School of Medicine, is all about the monthly GLP-1 shot. “The straight-up benefit of the once-monthly dose is you get 12 injections a year versus 52 a year,” he explains. That’s a whole lot less poking and prodding, and who wouldn’t want that?
These GLP-1 drugs are designed to bind to receptors in the body, regulating blood sugar and curbing those pesky hunger pangs. But here’s the kicker: while most of these drugs require weekly doses because the body breaks down their active ingredients in about seven days, Pfizer and Amgen are working on engineering new drugs that can last longer in the system. Pfizer’s berobenatide, for instance, cleverly clings to a protein in the blood called albumin, helping it stick around longer. Talk about a loyal drug!
In trials, berobenatide has helped patients lose an average of 12.3% of their body weight. And that’s not all – it’s also helping manage blood sugar levels for those with Type 2 diabetes. Side effects? Mostly gastrointestinal, but hey, that’s par for the course with these meds. “The GLP-1 receptor where the GLP-1 docks has got two signaling paths. This one [berobenatide] is driving one of those two,” Buse clarifies. So, it’s all about minimizing discomfort while maximizing results.
On the other hand, Amgen’s MariTide is also in the ring, using an antibody to prolong its effects. With results showing up to 20% weight loss after a year, this drug is proving to be a heavyweight contender. “It’s only 52 weeks, so it’s not a long-term effect,” says Murielle Veniant-Ellison, who heads Amgen’s obesity research. But let’s be real – a little less frequent medication could be a game changer for those who struggle with sticking to a schedule.
Dr. Susan Spratt from Duke Health thinks this could be a win for patients who find it hard to keep up with weekly doses. But she also warns that a monthly routine might not work for everyone. “Sometimes people need a routine and monthly might not be routine enough,” she notes. So, it’s all about finding what works best for you.
Take Taylor McDaniels, 25, from Pittsburgh, who’s usually on top of her weekly injections. “I haven’t been perfect,” she admits. Life happens, and sometimes you forget your shot. A monthly option could provide the flexibility she needs, but she’s still got questions about side effects and effectiveness.
As these pharmaceutical giants continue to innovate, the future of weight loss drugs looks brighter than ever. With fewer injections and potentially better adherence, it’s time to embrace this new era of health. Who’s ready to say goodbye to the weekly grind and hello to a more fabulous way of managing weight? The countdown to fewer injections starts now!
https://www.youtube.com/nbcnews